WallStreetZenWallStreetZen

NASDAQ: VIRX
Viracta Therapeutics Inc Stock

$1.08+0.00 (+0%)
Updated Mar 27, 2024
VIRX Price
$1.08
Fair Value Price
-$0.34
Market Cap
$42.41M
52 Week Low
$0.43
52 Week High
$2.38
P/E
-0.82x
P/B
2.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$51.06M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.1
Operating Cash Flow
-$40M
Beta
1.27
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VIRX Overview

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VIRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VIRX ($1.08) is overvalued by 415.09% relative to our estimate of its Fair Value price of -$0.34 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VIRX ($1.08) is not significantly undervalued (415.09%) relative to our estimate of its Fair Value price of -$0.34 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VIRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VIRX due diligence checks available for Premium users.

Be the first to know about important VIRX news, forecast changes, insider trades & much more!

VIRX News

Valuation

VIRX fair value

Fair Value of VIRX stock based on Discounted Cash Flow (DCF)
Price
$1.08
Fair Value
-$0.34
Undervalued by
415.09%
VIRX ($1.08) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VIRX ($1.08) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VIRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VIRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.82x
Industry
14.3x
Market
44.45x

VIRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.32x
Industry
6.2x
VIRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VIRX's financial health

Profit margin

Revenue
$0.0
Net Income
-$13.8M
Profit Margin
0%
VIRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$56.7M
Liabilities
$38.4M
Debt to equity
2.1
VIRX's short-term assets ($54.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VIRX's short-term assets ($54.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VIRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VIRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.0M
Investing
$9.3M
Financing
$218.0k
VIRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VIRX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VIRX$42.41M0.00%-0.82x2.32x
TLSA$42.65M-2.11%-2.78x2.18x
BCTX$42.67M+5.12%-3.34x-5.29x
VYNE$41.73M+4.59%-1.06x0.47x
IPA$41.31M+3.29%-3.81x1.13x

Viracta Therapeutics Stock FAQ

What is Viracta Therapeutics's quote symbol?

(NASDAQ: VIRX) Viracta Therapeutics trades on the NASDAQ under the ticker symbol VIRX. Viracta Therapeutics stock quotes can also be displayed as NASDAQ: VIRX.

If you're new to stock investing, here's how to buy Viracta Therapeutics stock.

What is the 52 week high and low for Viracta Therapeutics (NASDAQ: VIRX)?

(NASDAQ: VIRX) Viracta Therapeutics's 52-week high was $2.38, and its 52-week low was $0.43. It is currently -54.62% from its 52-week high and 151.16% from its 52-week low.

How much is Viracta Therapeutics stock worth today?

(NASDAQ: VIRX) Viracta Therapeutics currently has 39,272,434 outstanding shares. With Viracta Therapeutics stock trading at $1.08 per share, the total value of Viracta Therapeutics stock (market capitalization) is $42.41M.

Viracta Therapeutics stock was originally listed at a price of $8,190.00 in Sep 27, 2005. If you had invested in Viracta Therapeutics stock at $8,190.00, your return over the last 18 years would have been -99.99%, for an annualized return of -39.12% (not including any dividends or dividend reinvestments).

How much is Viracta Therapeutics's stock price per share?

(NASDAQ: VIRX) Viracta Therapeutics stock price per share is $1.08 today (as of Mar 27, 2024).

What is Viracta Therapeutics's Market Cap?

(NASDAQ: VIRX) Viracta Therapeutics's market cap is $42.41M, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Viracta Therapeutics's market cap is calculated by multiplying VIRX's current stock price of $1.08 by VIRX's total outstanding shares of 39,272,434.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.